ENTPD3 Sorting of Stem Cell-Derived β-Cells for Mature Insulin Secretion
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods for differentiating β-like cells from human pluripotent stem cells result in cells that phenotypically and functionally resemble fetal β-cells rather than mature adult β-cells, which are not ideal for cell replacement therapy due to their insulin secretion profile, and existing approaches to improve maturation have been limited in success.
Innovation Solution
The use of an insulin promoter-driven transgenic fluorescence reporter gene to sort and reaggregate stem cell-derived β-cells into enhanced beta-like clusters (seBCs), combined with the identification of the cell surface marker ENTPD3, allows for the isolation of the most mature β-cells, which can then be used for cell therapy treatments.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Manufacturing precision
If stem cell-derived β-cells are differentiated using current methods, then β-like cells are produced, but they resemble fetal β-cells rather than mature adult β-cells, resulting in suboptimal insulin secretion profile
Solution Approach 1:
The patent applies preliminary action by using an insulin promoter-driven transgenic fluorescence reporter gene to identify and sort mature β-cells before transplantation. This allows selection of cells with the desired mature phenotype and insulin secretion profile prior to therapy, resolving the contradiction between producing β-like cells and ensuring they have the correct maturity and function.
Solution Approach 2:
The patent applies local quality by creating enhanced beta-like clusters (seBCs) with heterogeneous cell populations where only specific subpopulations expressing the fluorescence marker are selected. This local identification and sorting approach ensures that the transplanted cells have the specific mature qualities needed for reliable insulin secretion.
2Manufacturing precision
If existing approaches to improve maturation are used, then some maturation enhancement is achieved, but success is limited and mature adult β-cell characteristics are not fully obtained
Solution Approach 1:
The patent replaces mechanical/difficult maturation improvement approaches with a molecular biology-based sorting system. Instead of relying on complex maturation protocols with limited success, the invention uses genetic reporting and fluorescence-activated cell sorting to directly identify and isolate mature β-cells, achieving both high maturation precision and therapeutic productivity.
3Quantity of substance
If heterogeneous populations of stem cell-derived β-cells are used for transplantation, then more cells are available, but functionality is reduced due to inclusion of immature cells
Solution Approach 1:
The patent applies the extraction principle by isolating and sorting the specific subpopulation of mature β-cells that express the fluorescence marker from the heterogeneous stem cell-derived population. This extraction of the desired cell type ensures both sufficient quantity for transplantation and high functional reliability, as only cells with the correct mature phenotype are selected.
Data Source
AI summary
Disclosed herein are methods, systems, and compositions for enhancing the effectiveness of β-cell (Beta-cell)-based therapies. Also disclosed herein are methods, systems, and compositions related to identifying, sorting and separating heterogeneous populations of stem cell-derived pancreatic β-cells (sBCs) into more useful and functionally homogeneous cell populations. In many embodiments, the most mature and functional of the sBCs are identified and live-sorted using the cell surface protein Ectonucleoside Triphosphate Diphosphohydrolase-3 (ENTP3), which is also referred to as CD39L3. The presently disclosed methods, systems, and compositions are useful for cell therapies, for example replacement therapy. In many embodiments the disclosed systems, methods, and compositions are useful in treatments for diabetes. In some embodiments, the disclosed methods, systems, and compositions may be useful in treating, preventing, and/or curing diabetes, for example type-1 diabetes.